{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:58:40Z","timestamp":1774159120206,"version":"3.50.1"},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00108-020-00766-4","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T09:02:46Z","timestamp":1583312566000},"page":"530-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Febuxostat oder Allopurinol bei Patienten mit Gicht","Febuxostat or allopurinol in patients with gout"],"prefix":"10.1007","volume":"61","author":[{"given":"R.","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mischkewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"766_CR1","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.40583","volume":"70","author":"H Choi","year":"2018","unstructured":"Choi\u00a0H, Neogi\u00a0T, Stamp\u00a0L, Dalbeth\u00a0N, Terkeltaub\u00a0R (2018) New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert. Arthritis Rheumatol 70:1702\u20131709","journal-title":"Arthritis Rheumatol"},{"key":"766_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10067-018-4396-4","volume":"38","author":"TLTA Jansen","year":"2019","unstructured":"Jansen\u00a0TLTA, Janssen\u00a0M (2019) Gout\u00a0lessons\u00a0from\u00a02018:\u00a0CARES, a\u00a0direct comparison of febuxostat vs allopurinol, and\u00a0CANTOS,\u00a0IL1\u00a0blocker\u00a0for\u00a0cardiovascular\u00a0risk\u00a0minimisation. Clin Rheumatol 38:263\u2013265","journal-title":"Clin Rheumatol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-020-00766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:24:10Z","timestamp":1614817450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-020-00766-4"}},"subtitle":["Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)"],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":2,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00766-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"4 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Alten hat Vortragshonorare von Menarini sowie Berlin Chemie erhalten. M.\u00a0Mischkewitz und S.\u00a0Nitschmann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}